Celcuity (CELC) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Celcuity (NASDAQ:CELC) from a strong-buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. “

Separately, ValuEngine raised Celcuity from a hold rating to a buy rating in a report on Friday, March 15th.

Shares of NASDAQ CELC traded up $0.27 during midday trading on Tuesday, hitting $21.67. 131 shares of the company’s stock were exchanged, compared to its average volume of 8,097. Celcuity has a 12-month low of $18.22 and a 12-month high of $31.00. The firm has a market capitalization of $221.23 million, a price-to-earnings ratio of -29.28 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Tuesday, February 26th. The company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. As a group, analysts anticipate that Celcuity will post -0.86 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Strs Ohio lifted its position in Celcuity by 112.5% in the 4th quarter. Strs Ohio now owns 1,700 shares of the company’s stock worth $40,000 after buying an additional 900 shares during the last quarter. Northern Trust Corp lifted its position in Celcuity by 2.0% in the 4th quarter. Northern Trust Corp now owns 61,888 shares of the company’s stock worth $1,484,000 after buying an additional 1,223 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Celcuity by 13,655.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 1,229 shares during the last quarter. Kessler Investment Group LLC lifted its position in Celcuity by 46.3% in the 1st quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock worth $154,000 after buying an additional 2,222 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Celcuity by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock worth $840,000 after buying an additional 2,930 shares during the last quarter. Institutional investors own 21.94% of the company’s stock.

About Celcuity

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Recommended Story: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Celcuity (CELC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.